Comprehensive Thyroid Assessment in a Prospective Japanese Cohort: Epidemiology, Determinants, and Ultrasonographic Reference Ranges

Satoko Shimazu-Kuwahara[1], Ichiro Yamauchi[2*], Sachiko Kawashima[1], Makiko Tatsumi[1], Takuro Hakata[2], Yoriko Sakane[2,3], Masahiro Yakami[1], Kosuke Inoue[4], Daisuke Yabe[2], Mayumi Inoue[1]

*Corresponding author

[1]Preemptive Medicine and Lifestyle Disease Research Center, Kyoto University Hospital

[2]Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine

[3]Sugawa Clinic

[4]Health Promotion and Human Behavior, School of Public Health, Kyoto University Graduate School of Medicine

Key Words: Thyroid function test, Thyroid dysfunction, FDG-PET, Ultrasonography, TPOAb

Address correspondence to:

Ichiro Yamauchi

Department of Diabetes, Endocrinology and Nutrition

Kyoto University Graduate School of Medicine

54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan

Phone: +81-75-751-3560

E-mail: ichiroy@kuhp.kyoto-u.ac.jp

Funding

This study was supported by Medical Corporation Midtown Clinic and Japan Foundation for Applied Enzymology.

Disclosure summary

SSK, SK, MT, MY, and MI are affiliated with the Preemptive Medicine and Lifestyle Disease Research Center, Kyoto University Hospital, which is funded by Medical Corporation Midtown Clinic. IY and TH serve as advisors to the Center. SSK, SK, MT, MY, and MI received research funding from Medical Corporation Midtown Clinic.

ABSTRACT

Context: A comprehensive evaluation of thyroid disease and health through multimodal assessment is warranted.

Objective: To clarify the epidemiology and clinical significance of abnormal findings on thyroid examinations in the general population.

Design: Prospective cohort study conducted between April 1, 2016, and December 31, 2021.

Setting: Japanese adults undergoing health checkups at the Preemptive Medicine and Lifestyle Disease Research Center, Kyoto University Hospital.

Main Outcome Measures: All subjects underwent thyroid function tests, ultrasonography, and ^{18}F-fluorodeoxyglucose-positron emission tomography (FDG-PET); anti-thyroperoxidase antibody (TPOAb) titers were measured in a subset of subjects.

Results: In the original cohort of 4,407 subjects (2,643 males and 1,764 females), the prevalence of thyroid dysfunction, increased blood flow on ultrasonography, diffuse thyroid FDG uptake, and thyroid nodules was 5.81%, 2.45%, 3.43%, and 39.71%, respectively; all were more frequent in females. Among 2,420 subjects with TPOAb measurements, TPOAb positivity was 7.19% and was significantly associated with thyroid dysfunction only at titers ≥ 128 IU/mL. Multivariate analyses identified age, sex, and thyroid volume as major determinants of thyroid function. Using data from 1,840 subjects without any thyroid abnormalities, we established sex-specific reference ranges for thyroid dimensions and found their correlations with age and body size.

Conclusions: This cohort provides epidemiological and physiological insights into thyroid health by integrating findings from thyroid function tests, ultrasonography, FDG-PET, and TPOAb measurements in the general population. Furthermore, the present study highlights associations across abnormal findings, relationships within thyroid physiology, and clinical relevance of high-titer TPOAb.

Introduction

Thyroid diseases are common in the general population. Thyroid dysfunction is clinically important because, if left untreated, it can lead to multiple comorbidities. In the United Kingdom, the incidence of hypothyroidism is 0.41% per year in females and 0.06% per year in males, whereas that of hyperthyroidism is 0.08% per year in females and negligible in males (1). In the United States, the prevalence of overt and subclinical hypothyroidism is 0.3% and 4.3%, respectively, whereas that of overt and subclinical hyperthyroidism is 0.5% and 0.7% (2). When thyroid dysfunction is detected, its cause should be investigated using additional tests. Hashimoto's disease, the most frequent cause of hypothyroidism, is diagnosed by detecting thyroid autoantibodies, such as anti-thyroperoxidase (TPOAb) and anti-thyroglobulin antibodies (TgAb). In the United States, TPOAb and TgAb positivity has been reported in 13.0% and 11.5% of adults, respectively (2).

Thyroid ultrasonography is a key imaging modality for the diagnosis of thyroid diseases. Diffuse hypervascularity on color Doppler, known as thyroid inferno, is a hallmark of Graves' disease, although increased blood flow can also be observed in some cases of Hashimoto's thyroiditis (3). In addition, ultrasonography is essential for the detailed evaluation of thyroid nodules. The prevalence of thyroid nodules is high and increases with age, reaching nearly 50% when assessed using ultrasonography (4). ^{18}F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is widely used in oncological evaluations, and the thyroid gland occasionally exhibits FDG uptake. Diffuse thyroid FDG uptake suggests a high likelihood of Hashimoto's disease (5,6). Although the prevalence of diffuse thyroid FDG uptake has been reported (5,7), its clinical significance remains unclear.

Although thyroid diseases can be evaluated using multiple modalities, data on the relationships among these examinations are limited, particularly regarding ultrasonography and FDG-PET. The Fukushima Health Management Survey reported estimated thyroid

volume by ultrasonography from infancy through adolescence (8), whereas fewer data are available for adults (9,10). Moreover, in adults, the high prevalence of Hashimoto's thyroiditis and thyroid nodules complicates the identification of truly disease-free reference populations. Therefore, a cohort restricted to individuals with healthy thyroid glands is warranted to investigate thyroid physiology.

In 2016, we launched a prospective cohort study of Japanese adults in a health checkup setting. This cohort featured comprehensive phenotyping. For thyroid assessment, all subjects underwent thyroid function tests, thyroid ultrasonography, and FDG-PET; measurement of TPOAb was incorporated midway through the study. We aimed to clarify the epidemiology and clinical significance of abnormal findings detected in these thyroid examinations among the general population.

Methods

Subjects

A flow diagram of the enrollment process is shown in Figure 1. From April 1, 2016, to December 31, 2021, we enrolled 4,651 adults who underwent their initial health checkup at the Preemptive Medicine and Lifestyle Disease Research Center, Kyoto University Hospital. We excluded 5 individuals without blood tests and 111 who did not provide informed consent. In addition, 128 individuals were excluded because of current or past thyroid diseases, including Graves' disease (n = 37), levothyroxine replacement for hypothyroidism (n = 37), thyroid cancer (n = 36), surgery for thyroid nodules (n = 13), and a history of subacute thyroiditis (n = 5). A total of 4,407 subjects met the inclusion criteria for this study, and we defined this group as the Original cohort (Figure 1). As TPOAb measurements began partway through the study, we additionally analyzed the TPOAb cohort consisting of 2,420 subjects with available TPOAb results (Figure 1). A major strength of this study is the strict definition of subjects without thyroid abnormalities based on multimodal thyroid assessment.

Accordingly, we established the Thyroid-healthy cohort by excluding subjects with abnormal TSH levels, TPOAb positivity, increased blood flow, diffuse FDG uptake, or thyroid nodules (Figure 1). The study was approved by the Ethics Committee of Kyoto University Hospital (approval numbers R0619 and R3604), and written informed consent was obtained from all subjects.

Evaluation

Serum levels of TSH, free T4 (fT4), and free T3 (fT3) were measured using electrochemiluminescence immunoassays (Elecsys; Roche Diagnostics, Mannheim, Germany). Reference ranges were as follows: TSH, 0.500–5.000 μIU/mL; fT4, 0.880–1.620 ng/dL; and fT3, 2.33–4.00 pg/mL. TPOAb measurements were initiated on January 1, 2018, and were performed using an Elecsys assay (reference: < 16 IU/L). Thyroid ultrasonography was performed using an Aplio 500 system (Canon Medical System Corporation, Otawara, Japan) equipped with a linear transducer (PLT-1005BT; 6-cm footprint). We measured the isthmus thickness and, for each lobe, the transverse, anteroposterior, and longitudinal diameters. Lobe volume was calculated as the transverse diameter × anteroposterior diameter × longitudinal diameter × $\pi/6$, and total thyroid volume was obtained by summing volumes of both lobes. Blood flow was evaluated using color Doppler ultrasonography. The entire gland was systematically surveyed for nodules and cysts. Ultrasound cine loops were reviewed by a second sonographer for quality assurance. For FDG-PET, we focused on diffuse thyroid uptake and did not analyze focal uptake confined to nodules. FDG-PET images were independently reviewed by board-certified radiologists.

Statistical analyses

All statistical analyses were performed using JMP Pro version 18.0 (SAS Institute Inc., NC, USA). Unless otherwise specified, values are presented as the mean ± SD. As TSH values followed a log-normal distribution, statistical analyses were performed using log-transformed values. Continuous variables were compared using Student's *t*-test, and

categorical variables using Fisher's exact test. For trend analyses, we assigned the median value of each ordered category and modeled it as a continuous variable in regression analyses. Multivariable linear regression was used to assess independent associations. Pearson's correlation coefficients were calculated to evaluate correlations between variables. Significant differences were considered as $p < 0.05$.

Results

Prevalence of abnormal findings on thyroid examinations

The characteristics of the Original cohort are summarized in Table 1. The mean age was 52.9 ± 11.3 years; 2,643 (59.97%) were males and 1,764 (40.03%) were females. The serum levels of TSH, fT4, and fT3 were 1.952 ± 2.245 μIU/mL, 1.288 ± 0.200 ng/dL, and 3.08 ± 0.58 pg/mL, respectively. Significant sex-related differences were observed (Table 1). Males were slightly older and had larger anthropometric measurements than females. TSH levels were slightly lower in males than in females (1.859 vs. 2.091 μIU/mL, $p = 0.0001$), whereas fT4 and fT3 levels were higher in males (fT4, 1.313 vs. 1.250 ng/dL, $p < 0.0001$; fT3, 3.19 vs. 2.93 pg/mL, $p < 0.0001$).

Thyroid dysfunction was identified in 256 subjects (5.81%) (Figure 2A, Table 1). The most common pattern was subclinical hypothyroidism (n = 118; 2.68%), followed by subclinical thyrotoxicosis (n = 104; 2.36%), overt thyrotoxicosis (n = 27; 0.61%), and overt hypothyroidism (n = 7; 0.16%) (Figure 2B, Table 1). The characteristics of each group, categorized by thyroid dysfunction pattern, are shown in Table 2. Overt thyrotoxicosis was more common in younger subjects, whereas subclinical hypothyroidism predominated among older subjects and was more frequent in females.

Increased blood flow on thyroid ultrasonography was detected in 108 subjects (2.45%) and was significantly more common in females (4.14%) than in males (1.32%) (Figure 2C, Table 1). Diffuse thyroid FDG uptake was observed in 151 subjects (3.43%) and

was likewise more common in females (6.35%) than in males (1.48%) (Figure 2D, Table 1). Both increased blood flow and diffuse FDG uptake were often present in the subjects with overt thyroid dysfunction or subclinical hypothyroidism, especially those with overt hypothyroidism (Table 2). Thyroid nodules were found in 1,750 subjects (39.71%) (Figure 2E, Table 1). Based on the maximum diameter, 667 subjects (15.14%) had nodules < 5.0 mm, 705 (16.00%) had nodules 5.0–9.9 mm, 315 (7.15%) had nodules 10.0–19.9 mm, and 63 (1.43%) had nodules ≥ 20.0 mm (Figure 2F, Table 1). Females had a higher prevalence of nodules ≥ 5.0 mm than males (33.79% vs. 18.43%) (Table 1). The prevalence of nodules increased with age, whereas the prevalence of thyroid dysfunction, increased blood flow, and diffuse FDG uptake did not show significant age-related variations (Supplemental Table 1).

Association of clinical characteristics and abnormal findings with thyroid function

We subsequently assessed the relationship of clinical characteristics and abnormal findings with thyroid function. Although fT4 levels showed a significant correlation with log-transformed TSH levels ($r = -0.3829$, $p < 0.0001$) (Figure 3A), we excluded subjects whose thyroid function values were outside the main distribution for subsequent analyses (Figure 3B): those with TSH < 0.1 μIU/mL (n = 18), TSH > 10 μIU/mL (n = 13), and one subject with syndrome of inappropriate secretion of TSH (SITSH, n = 1). In this dataset restricted to subnormal thyroid function, older age was associated with higher TSH levels in both sexes (Figure 3C, Supplemental Table 2). Sex differences were observed in fT4 and fT3 trends: in males, both hormones decreased with age, whereas in females, only a slight age-related decline in fT3 was observed (Figure 3D and 3E, Supplemental Table 2). Height showed only a minor association with thyroid function, whereas body weight correlated positively with fT3 levels (Supplemental Figure 1, Supplemental Table 3 and 4). Body mass index (BMI) analysis showed that lean subjects had lower fT3 levels and obese subjects had higher fT3 levels in both sexes; no BMI-related trends were observed for TSH or fT4 (Figure 3F–3H, Supplemental Table 5).

We then examined the relationship between abnormal findings and thyroid function. Subjects with increased blood flow had higher TSH and lower fT4 levels, with no changes in fT3 levels (Figure 4A–4C, Supplemental Table 6). Diffuse FDG uptake was also associated with higher TSH and lower fT4 levels (Figure 4D–4F, Supplemental Table 6). Regarding thyroid nodules, only minor size-related trends were observed; nodules ≥ 20 mm were associated with lower TSH levels in females (Figure 4G–4I, Supplemental Table 7). Moreover, the estimated thyroid volume was analyzed using ultrasonography. Due to technical limitations, mainly the difficulty in measuring the longitudinal diameter, data were unavailable for 183 subjects, leaving 4,192 evaluable cases. Thyroid volume was negatively correlated with TSH and positively correlated with both fT4 and fT3 levels (Figure 4J–4L, Supplemental Table 8).

Association between TPOAb titers and thyroid function

We then analyzed the TPOAb cohort (n = 2,420), whose characteristics were similar to those of the Original cohort (Supplemental Table 9). TPOAb positivity was found in 174 subjects (7.19%), with a higher prevalence in females (96 of 938 subjects, 10.23%) than in males (78 of 1,482 subjects, 5.26%; $p < 0.0001$) (Figure 5A). Subjects with TPOAb positivity more frequently exhibited abnormal findings on thyroid examinations than those without TPOAb; thyroid dysfunction (13.22% vs. 4.94%, $p < 0.0001$), increased blood flow (28.16% vs. 1.11%, $p < 0.0001$), and diffuse FDG uptake (28.74% vs. 1.25%, $p < 0.0001$) (Figure 5B–5D, Supplemental Table 10). The prevalence of thyroid nodules did not differ between TPOAb-positive and TPOAb-negative subjects (40.80% vs. 39.45%, $p = 0.7478$) (Figure 5E, Supplemental Table 10).

We subsequently examined whether the TPOAb titer influenced these associations. Thyroid dysfunction, particularly hypothyroidism, was more frequent among subjects with TPOAb titers ≥ 128 IU/mL (Table 3). The prevalence of increased blood flow and diffuse FDG uptake also increased in a titer-dependent manner (Table 3). To further clarify the

relationship between TPOAb positivity and thyroid function, we excluded subjects whose thyroid function values were outside the main distribution (Figure 5F), as in Figure 3B: TSH < 0.1 μIU/mL (n = 11), TSH > 10 μIU/mL (n = 10), or SITSH (n = 1). In this dataset, TPOAb-positive subjects had higher TSH levels than TPOAb-negative subjects, whereas fT4 and fT3 levels remained unchanged (Figure 5G–5I, Supplemental Table 11). Analysis by titer showed that TSH elevation was observed only in subjects with TPOAb ≥ 128 IU/mL, with no corresponding changes in fT4 or fT3 levels (Supplemental Figure 2, Supplemental Table 11).

From these analyses, we identified age, sex, BMI, increased blood flow, diffuse FDG uptake, thyroid volume, and TPOAb titers ≥ 128 IU/mL as potential determinants of thyroid function. To assess their relative contributions, we conducted multivariable analyses within the TPOAb cohort after excluding subjects lacking thyroid volume data (n = 130), those with nodules ≥ 20 mm, and those with outlying thyroid function values (TSH < 0.1 μIU/mL, n = 6; TSH > 10 μIU/mL, n = 10; SITSH, n = 1). Among the 2,239 subjects analyzed, Model 1, which included only demographic and anthropometric variables, showed an age-related increase in TSH and decreases in fT4 and fT3 levels. Males had lower TSH and higher fT4 and fT3 levels than females, and BMI showed a positive correlation exclusively with fT3 levels (Table 4). Model 2, which incorporated all identified factors, reproduced the age-related changes, but the association between TSH levels and sex was no longer significant. BMI was weakly associated with TSH and fT3 levels in both sexes. Among the factors obtained from thyroid examinations, thyroid volume was negatively associated with TSH and positively associated with fT4 and fT3 levels; increased blood flow and TPOAb ≥ 128 IU/mL were linked to higher TSH levels; and increased blood flow and diffuse FDG uptake were associated with lower fT4 levels. In summary, age and sex remain the dominant determinants of thyroid function, while ultrasonographic findings have a significant influence.

Reference ranges and factors associated with thyroid size

We further investigated factors influencing thyroid size using the Thyroid-healthy

241 cohort (n = 1,840) without any thyroid abnormalities. The characteristics of this cohort are
242 presented in Table 5. Subjects with nodules < 10 mm were included, given their high
243 prevalence (33.37%). All thyroid size parameters, including the isthmus thickness, the
244 transverse, anteroposterior, and longitudinal diameters of each lobe, were larger in males than
245 in females (Table 5). Several sex-independent correlations were observed: the longitudinal
246 diameter was negatively correlated with age (Figure 6A–6D, Supplemental Table 12) and
247 positively correlated with height (Figure 6E–6H, Supplemental Table 13). Body weight and
248 BMI were positively correlated with the isthmus thickness and the transverse and
249 anteroposterior diameters (Figure 6I–6L, Supplemental Figure 3, Supplemental Table 14 and
250 15). Consequently, thyroid volume was positively correlated with height, body weight, and
251 BMI (Supplemental Figure 4, Supplemental Table 12–15).

252 As thyroid nodules measuring 5.0–9.9 mm could potentially affect lobe size in both
253 sexes (Supplemental Table 16), we performed an additional analysis by excluding 296
254 subjects with nodules in this size range. Multiple regression analysis confirmed that sex
255 remained a significant determinant of thyroid size, independent of height and body weight
256 (Supplemental Table 17). The longitudinal diameter was significantly correlated with age and
257 height. The transverse and anteroposterior diameters were positively correlated with body
258 weight. Thyroid volume was strongly correlated with body weight, but its association with
259 height was no longer significant.

260 Finally, we calculated reference ranges for thyroid size using data from 1,544
261 Thyroid-healthy cohort subjects without nodules ≥ 5.0 mm (Table 6). Consistent with the
262 findings in Table 5, the left lobe was smaller than the right lobe in both sexes. For the right
263 lobe, the transverse diameter measured 16.6 ± 2.8 mm in males and 14.1 ± 2.4 mm in
264 females; for the left lobe, it was 15.9 ± 2.8 mm and 14.3 ± 2.2 mm, respectively ($p < 0.0001$
265 for males, $p = 0.1904$ for females). The anteroposterior diameter of the right lobe was 14.7 ±
266 2.5 mm in males and 12.1 ± 2.1 mm in females, while the left lobe measured 12.9 ± 2.6 mm

and 10.4 ± 2.4 mm, respectively ($p < 0.0001$ for both sexes). The longitudinal diameter of the right lobe was 50.2 ± 5.3 mm in males and 48.5 ± 5.6 mm in females; for the left lobe, 47.9 ± 5.7 mm and 45.7 ± 6.3 mm, respectively ($p < 0.0001$ for both sexes). Thus, the left lobe was consistently smaller than the right lobe in both sexes, particularly in the anteroposterior and longitudinal diameters.

Discussion

In this prospective cohort study of the Japanese general population, we comprehensively analyzed data on thyroid examinations, including thyroid function tests, ultrasonography, FDG-PET, and TPOAb measurements. In addition to documenting the prevalence of thyroid dysfunction, we present epidemiological findings. As expected, females were more susceptible to thyroid dysfunction and other abnormalities than males. We also identified factors associated with thyroid function, demonstrating that age, sex, and thyroid volume were dominant determinants. By rigorously excluding subjects with thyroid abnormalities, we defined the Thyroid-healthy cohort and established reference ranges for thyroid size. Furthermore, we identified sex differences and demonstrated that thyroid dimensions correlated with age and body size.

Given that racial differences may affect thyroid function and disease prevalence, our East Asian cohort provides valuable evidence. A meta-analysis of European epidemiological data reported a prevalence of 4.59% for subclinical hypothyroidism, 0.62% for overt hypothyroidism, 0.50% for subclinical hyperthyroidism, and 0.35% for overt hyperthyroidism (11). In the United States, the National Health and Nutrition Examination Survey (NHANES; 2007–2012) found prevalence of 4.3%, 0.33%, 3.20%, and 0.2%, respectively (12). In our cohort, the corresponding values were 2.68%, 0.16%, 2.36% and 0.61%. Another Japanese cohort study of healthy individuals reported an overall prevalence of hypothyroidism of 1.39% (13). These comparisons suggest that hypothyroidism is less

common and thyrotoxicosis is more common in Japan than in Europe or the United States. Japan is considered an iodine-sufficient to iodine-excess country (14), and excessive iodine intake is generally associated with an increased risk of developing hypothyroidism (15). In this context, the observed differences are unlikely to be explained by iodine status and may instead reflect other factors, such as racial or genetic differences.

Our cohort also provides epidemiological insights into FDG-PET, ultrasonography, and TPOAb titers. Increased blood flow on ultrasonography was observed in 2.45% of the subjects, with a marked sex difference (1.32% in males vs. 4.14% in females). Schulz *et al.* reported that increased blood flow can occur in hypothyroidism and is strongly associated with elevated serum TSH levels (16). To date, its significance has not been evaluated in population-based cohorts without known thyroid diseases. While ultrasonography is subject to inter-operator variability, the relevance of our findings is supported by their association with thyroid dysfunction, which was more common in subjects with increased blood flow. Furthermore, increased blood flow was associated with TPOAb positivity, which is a well-established risk factor for hypothyroidism. Taken together, in settings where thyroid ultrasonography is readily available, the detection of increased blood flow may facilitate early suspicion of Hashimoto's disease and hypothyroidism.

While most previous studies have focused on focal thyroid FDG uptake, we specifically examined diffuse FDG uptake to clarify its significance in Hashimoto's disease and thyroid function. Previous studies have reported diffuse FDG uptake in 3.3% of 1102 cases (5) and 1.8% of 2594 cases (7). In our study, diffuse FDG uptake showed patterns similar to those of increased blood flow, with an overall prevalence of 3.43% (1.48% in males and 6.35% in females), which we report here for the first time. Diffuse FDG uptake was more common in subjects with thyroid dysfunction, particularly overt hypothyroidism, consistent with earlier reports identifying diffuse FDG uptake as a surrogate marker for Hashimoto's disease (5,6). Moreover, diffuse FDG uptake has been reported as a predictive factor for immune-related

319 adverse events (irAEs) involving the thyroid gland in patients treated with immune checkpoint
320 inhibitors (17,18). Given that female patients are more susceptible to thyroid irAEs (17,19),
321 the high prevalence of diffuse FDG uptake in females may contribute to this increased risk.

322 A meta-analysis reported a prevalence of thyroid nodules of 24.83% detected on
323 thyroid ultrasonography (20). In our cohort, the prevalence of nodules ≥ 5.0 mm was similar
324 (24.58%). Data on size-specific prevalence are limited; for example, in the Epidemiological
325 Study of Health Effects in Fukushima Emergency Workers, nodules > 5.0 mm were observed
326 in 15.5% of participants (21). The difference from our cohort is likely attributable to sex
327 composition, as the Fukushima study population was predominantly male. In our cohort, the
328 prevalence of nodules ≥ 5.0 mm was lower in males (18.43%) than in females (33.79%).
329 Consistent with previous studies (22-24), we observed a higher prevalence in females and an
330 age-related increase in the frequency of nodules. Moreover, our size-stratified analyses
331 revealed that relatively large nodules were associated with lower TSH levels in females.

332 TPOAb was detected in 7.19% of the subjects in our cohort, with a higher prevalence
333 in females (10.23%) than in males (5.26%). In NHANES, the prevalence was 11.1% (7.2% in
334 males and 14.8% in females) (12), and in a Japanese health checkup cohort, it was 11.6% (7.2%
335 in males and 15.0% in females) (25). Thus, TPOAb positivity was less frequent in our study,
336 which may reflect differences in assay methodology: NHANES used a different immunoassay
337 and reference range, whereas the Japanese health checkup cohort used a radioimmunoassay kit.
338 Supporting this interpretation, a Chinese study that used the same manufacturer's assay as ours,
339 with a cut-off of < 34 IU/mL, reported a prevalence of 7.98% (6.12% in males and 9.90% in
340 females) (26), closely matching our results.

341 Importantly, we identified the clinical relevance of high TPOAb titers. As shown in
342 Table 3, the prevalence of increased blood flow and diffuse FDG uptake elevated in a titer-
343 dependent manner, whereas the prevalence of thyroid dysfunction increased only in subjects
344 with TPOAb titers ≥ 128 IU/mL. Similarly, a previous cohort study found no significant

increase in overt hypothyroidism among subjects with TPOAb titers of 35–105 IU/mL, but a marked increase among those with TPOAb titers of 106–350 IU/mL (27). These findings suggest that low-titer TPOAb positivity reflects a relatively mild autoimmune response that may be self-limiting and insufficient to cause thyroid dysfunction. However, given our cross-sectional design, we cannot exclude the possibility that low-titer positivity may predict future thyroid dysfunction. Nonetheless, low-titer TPOAb positivity is unlikely to confer a short-term risk of hypothyroidism.

We further investigated the factors associated with thyroid function, incorporating physiological perspectives. TSH levels were higher in females, whereas fT4 and fT3 levels were higher in males. Although this tendency has been reported in other cohorts (2,28,29), detailed statistical analyses are lacking. To address the potential bias from the higher prevalence of thyroid abnormalities in females, we confirmed sex-related differences in thyroid function using multivariate regression analyses. Age was another major determinant. TSH levels increased with age in both sexes, whereas fT4 and fT3 levels declined with age in males, with minimal associations observed in females. Similar patterns have been reported, with estrogen proposed as a contributing factor (30).

The association between low body weight and low T3 levels is well recognized in non-thyroidal illness, whereas the relationship between obesity and thyroid function remains controversial (31). In our cohort, BMI was positively correlated with fT3 levels in both sexes and TSH levels in females; both associations remained significant in multivariate analyses. As fT3 elevation was not accompanied by changes in fT4 levels, the involvement of iodothyronine deiodinases is likely. Type 2 iodothyronine deiodinase, which exerts a greater influence on circulating fT3 levels than type 1 (32), may mediate this effect, whereas type 3 iodothyronine deiodinase reduces fT3 levels. The clinical importance of type 2 iodothyronine deiodinase is supported by evidence that its pathogenic variant, Thr92Ala, is associated with reduced fT3 levels (33). The observed TSH elevation in females is also noteworthy; one

371 possible mechanism is leptin-mediated stimulation of thyrotropin-releasing hormone
372 secretion, given that females have higher circulating leptin levels (34,35) and obesity
373 increases leptin production (36-38).

374 Multivariate analyses confirmed that these factors independently determined thyroid
375 function. Abnormal findings on thyroid examinations were also associated with thyroid
376 function, even within the physiological range. However, diffuse FDG uptake and TPOAb
377 titers ≥ 128 IU/mL showed weaker associations than increased blood flow and thyroid
378 volume: diffuse FDG uptake was associated only with fT4, TPOAb titers ≥ 128 IU/mL only
379 with TSH, whereas increased blood flow and thyroid volume were associated with both TSH
380 and fT4 levels. This discrepancy may reflect that ultrasonographic changes indicate structural
381 alterations in the thyroid gland, whereas immune activity detected by FDG-PET or TPOAb
382 positivity alone may be insufficient to cause thyroid dysfunction.

383 Another strength of the present study is the rigorous assessment of thyroid
384 abnormalities, which enabled us to define the Thyroid-healthy cohort with no abnormal
385 findings on any thyroid examination. Using this cohort, we performed a detailed analysis of
386 thyroid size. First, males in our cohort had larger thyroid glands, independent of age, height,
387 and body weight. Sex differences in thyroid size have been consistently reported (39-41), and
388 our findings reaffirm this observation. Second, we observed a negative correlation between
389 age and the longitudinal diameter. Although age-related changes in thyroid size remain
390 controversial (40-42), this association may explain why we did not detect significant age
391 effects on other parameters (the isthmus thickness, the transverse diameter, and the
392 anteroposterior diameter) and why previous studies focusing on thyroid volume may have
393 failed to detect size changes (43), as thyroid volume is less sensitive to alterations in a single
394 dimension. Third, we identified a positive correlation between height and the longitudinal
395 diameter, whereas body weight was positively correlated with the isthmus thickness and the
396 transverse and anteroposterior diameters. This discrepancy is intriguing and raises the

397 possibility that the thyroid gland may grow predominantly in the longitudinal dimension in
398 proportion to height.

399 Finally, we established reference ranges for individual thyroid dimensions using
400 ultrasonography. While previous reports have provided regional reference values for thyroid
401 volume (43), to our knowledge, none have reported ranges for each parameter, namely, the
402 isthmus thickness, the transverse diameter, the anteroposterior diameter, and the longitudinal
403 diameter. We determined the reference values using strict criteria, excluding all subjects with
404 any abnormal findings on thyroid examinations or with nodules ≥ 5.0 mm, thereby ensuring a
405 robust reference set. We hope that these sex-specific reference values will serve as a useful tool
406 for evaluating thyroid enlargement in clinical practice.

407 This study has several limitations. As Japan is an iodine-sufficient country owing to
408 seaweed consumption (44), our results may differ from those in iodine-deficient regions. As
409 our cohort was composed almost entirely of Japanese individuals, racial differences should be
410 considered. Despite the peer review of ultrasonographic parameters, inter-operator variability
411 cannot be completely excluded. Diffuse FDG uptake was assessed qualitatively rather than
412 quantitatively, precluding the establishment of cutoff values. TgAb was not measured, and
413 inclusion of this parameter might have yielded additional insights.

414 In summary, this prospective cohort study of Japanese adults reported the prevalence
415 of thyroid dysfunction and abnormal findings on thyroid examinations and integrated
416 epidemiological data from ultrasonography, FDG-PET, and TPOAb measurements. We found
417 that TPOAb levels become clinically significant at titers ≥ 128 IU/mL and that age, sex, and
418 thyroid volume are dominant determinants of thyroid function. The Thyroid-healthy cohort,
419 defined through our stringent screening, enabled us to establish sex-specific reference ranges
420 for thyroid dimensions and confirm associations between thyroid size, age, and body size.
421 These findings provide comprehensive epidemiological and physiological evidence in
422 thyroid health and research.

Acknowledgments

We are grateful to the staff of the Preemptive Medicine and Lifestyle Disease Research Center for their assistance in collecting the data analyzed in this study. We also thank the ultrasound technologists for their expertise in performing thyroid ultrasonography and for their careful review of the images.

References

1. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, Young ET. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. *Clin Endocrinol (Oxf)*. 1995;43(1):55-68.

2. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*. 2002;87(2):489-499.

3. Ceylan I, Yener S, Bayraktar F, Secil M. Roles of ultrasound and power Doppler ultrasound for diagnosis of Hashimoto thyroiditis in anti-thyroid marker-positive euthyroid subjects. *Quant Imaging Med Surg*. 2014;4(4):232-238.

4. Mazzaferri EL. Management of a solitary thyroid nodule. *N Engl J Med*. 1993;328(8):553-559.

5. Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y, Horiuchi M. Chronic thyroiditis: diffuse uptake of FDG at PET. *Radiology*. 1998;207(3):775-778.

6. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, Peller PJ, Bahn RS, Lowe VJ. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. *J Nucl Med*. 2007;48(6):896-901.

449 **7.** Chen W, Parsons M, Torigian DA, Zhuang H, Alavi A. Evaluation of thyroid FDG
450 uptake incidentally identified on FDG-PET/CT imaging. *Nucl Med Commun*.
451 2009;30(3):240-244.
452 **8.** Suzuki S, Midorikawa S, Fukushima T, Shimura H, Ohira T, Ohtsuru A, Abe M,
453 Shibata Y, Yamashita S, Suzuki S. Systematic determination of thyroid volume by
454 ultrasound examination from infancy to adolescence in Japan: the Fukushima Health
455 Management Survey. *Endocr J*. 2015;62(3):261-268.
456 **9.** Hegedüs L, Perrild H, Poulsen LR, Andersen JR, Holm B, Schnohr P, Jensen G,
457 Hansen JM. The determination of thyroid volume by ultrasound and its relationship to
458 body weight, age, and sex in normal subjects. *J Clin Endocrinol Metab*.
459 1983;56(2):260-263.
460 **10.** Gómez JM, Maravall FJ, Gómez N, Gumà A, Soler J. Determinants of thyroid volume
461 as measured by ultrasonography in healthy adults randomly selected. *Clin Endocrinol*
462 *(Oxf)*. 2000;53(5):629-634.
463 **11.** Garmendia Madariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The
464 incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. *J Clin*
465 *Endocrinol Metab*. 2014;99(3):923-931.
466 **12.** Zhang X, Wang Y, Wang H, Zhang X. Trends in Prevalence of Thyroid Dysfunction
467 and its Associations With Mortality Among US Participants, 1988-2012. *J Clin*
468 *Endocrinol Metab*. 2024;109(2):e657-e666.
469 **13.** Konno N, Yuri K, Taguchi H, Miura K, Taguchi S, Hagiwara K, Murakami S.
470 Screening for thyroid diseases in an iodine sufficient area with sensitive thyrotrophin
471 assays, and serum thyroid autoantibody and urinary iodide determinations. *Clin*
472 *Endocrinol (Oxf)*. 1993;38(3):273-281.
473 **14.** Katagiri R, Asakura K, Sasaki S, Hirota N, Notsu A, Miura A, Todoriki H, Fukui M,
474 Date C. Estimation of habitual iodine intake in Japanese adults using 16 d diet records

475 over four seasons with a newly developed food composition database for iodine. *Br J*
476 *Nutr*. 2015;114(4):624-634.
477 **15.** Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, Yang
478 F, Dai H, Yu Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, Tong Y,
479 Wang W, Gao T, Li C. Effect of iodine intake on thyroid diseases in China. *N Engl J*
480 *Med*. 2006;354(26):2783-2793.
481 **16.** Schulz SL, Seeberger U, Hengstmann JH. Color Doppler sonography in
482 hypothyroidism. *Eur J Ultrasound*. 2003;16(3):183-189.
483 **17.** Yamauchi I, Yasoda A, Matsumoto S, Sakamori Y, Kim YH, Nomura M, Otsuka A,
484 Yamasaki T, Saito R, Kitamura M, Kitawaki T, Hishizawa M, Kawaguchi-Sakita N,
485 Fujii T, Taura D, Sone M, Inagaki N. Incidence, features, and prognosis of immune-
486 related adverse events involving the thyroid gland induced by nivolumab. *PLoS One*.
487 2019;14(5):e0216954.
488 **18.** Yamauchi I, Yabe D. Best practices in the management of thyroid dysfunction induced
489 by immune checkpoint inhibitors. *Eur Thyroid J*. 2025;14(1):e240328.
490 **19.** Muir CA, Tsang VHM, Menzies AM, Clifton-Bligh RJ. Immune Related Adverse
491 Events of the Thyroid - A Narrative Review. *Front Endocrinol (Lausanne)*.
492 2022;13:886930.
493 **20.** Mu C, Ming X, Tian Y, Liu Y, Yao M, Ni Y, Liu Y, Li Z. Mapping global
494 epidemiology of thyroid nodules among general population: A systematic review and
495 meta-analysis. *Front Oncol*. 2022;12:1029926.
496 **21.** Imaizumi M, Sobue T, Taniguchi N, Miyagawa M, Momose T, Yoshinaga S,
497 Yamamoto S, Ohishi W, Kitamura H, Zha L, Okubo T. Protocol and Progress of a
498 Thyroid Study in the Epidemiological Study of Health Effects in Fukushima
499 Emergency Workers. *Disaster Med Public Health Prep*. 2025;19:e108.
500 **22.** Brander A, Viikinkoski P, Nickels J, Kivisaari L. Thyroid gland: US screening in a

501 random adult population. *Radiology*. 1991;181(3):683-687.
502 **23.** Kwong N, Medici M, Angell TE, Liu X, Marqusee E, Cibas ES, Krane JF, Barletta
503 JA, Kim MI, Larsen PR, Alexander EK. The Influence of Patient Age on Thyroid
504 Nodule Formation, Multinodularity, and Thyroid Cancer Risk. *J Clin Endocrinol*
505 *Metab*. 2015;100(12):4434-4440.
506 **24.** Li Y, Jin C, Li J, Tong M, Wang M, Huang J, Ning Y, Ren G. Prevalence of Thyroid
507 Nodules in China: A Health Examination Cohort-Based Study. *Front Endocrinol*
508 *(Lausanne)*. 2021;12:676144.
509 **25.** Kasagi K, Takahashi N, Inoue G, Honda T, Kawachi Y, Izumi Y. Thyroid function in
510 Japanese adults as assessed by a general health checkup system in relation with
511 thyroid-related antibodies and other clinical parameters. *Thyroid*. 2009;19(9):937-944.
512 **26.** Zhang M, Ni W, Zhang L, Fan K, Sun Y, Liu C, Xu S. Age-specific association
513 between thyroid autoimmunity and hypothyroidism in Chinese adults aged over 65
514 years: a cross-sectional study. *Front Endocrinol (Lausanne)*. 2023;14:1216308.
515 **27.** Walsh JP, Bremner AP, Feddema P, Leedman PJ, Brown SJ, O'Leary P. Thyrotropin
516 and thyroid antibodies as predictors of hypothyroidism: a 13-year, longitudinal study
517 of a community-based cohort using current immunoassay techniques. *J Clin*
518 *Endocrinol Metab*. 2010;95(3):1095-1104.
519 **28.** Yamada S, Horiguchi K, Akuzawa M, Sakamaki K, Yamada E, Ozawa A, Kobayashi
520 I, Shimomura Y, Okamoto Y, Andou T, Andou Y, Yamada M. The Impact of Age- and
521 Sex-Specific Reference Ranges for Serum Thyrotropin and Free Thyroxine on the
522 Diagnosis of Subclinical Thyroid Dysfunction: A Multicenter Study from Japan.
523 *Thyroid*. 2023;33(4):428-439.
524 **29.** Meng Z, Liu M, Zhang Q, Liu L, Song K, Tan J, Jia Q, Zhang G, Wang R, He Y, Ren
525 X, Zhu M, He Q, Wang S, Li X, Hu T, Liu N, Upadhyaya A, Zhou P, Zhang J. Gender
526 and Age Impacts on the Association Between Thyroid Function and Metabolic

527 Syndrome in Chinese. *Medicine (Baltimore)*. 2015;94(50):e2193.
528 **30.** Völzke H, Alte D, Kohlmann T, Lüdemann J, Nauck M, John U, Meng W. Reference
529 intervals of serum thyroid function tests in a previously iodine-deficient area. *Thyroid*.
530 2005;15(3):279-285.
531 **31.** Fontenelle LC, Feitosa MM, Severo JS, Freitas TE, Morais JB, Torres-Leal FL,
532 Henriques GS, do Nascimento Marreiro D. Thyroid Function in Human Obesity:
533 Underlying Mechanisms. *Horm Metab Res*. 2016;48(12):787-794.
534 **32.** Yamauchi I, Sakane Y, Yamashita T, Hakata T, Sugawa T, Fujita H, Okamoto K, Taura
535 D, Hirota K, Ueda Y, Fujii T, Yasoda A, Inagaki N. Thyroid hormone economy in
536 mice overexpressing iodothyronine deiodinases. *FASEB J*. 2022;36(2):e22141.
537 **33.** Castagna MG, Dentice M, Cantara S, Ambrosio R, Maino F, Porcelli T, Marzocchi C,
538 Garbi C, Pacini F, Salvatore D. DIO2 Thr92Ala Reduces Deiodinase-2 Activity and
539 Serum-T3 Levels in Thyroid-Deficient Patients. *J Clin Endocrinol Metab*.
540 2017;102(5):1623-1630.
541 **34.** Rosenbaum M, Nicolson M, Hirsch J, Heymsfield SB, Gallagher D, Chu F, Leibel
542 RL. Effects of gender, body composition, and menopause on plasma concentrations of
543 leptin. *J Clin Endocrinol Metab*. 1996;81(9):3424-3427.
544 **35.** Ostlund RE, Jr., Yang JW, Klein S, Gingerich R. Relation between plasma leptin
545 concentration and body fat, gender, diet, age, and metabolic covariates. *J Clin*
546 *Endocrinol Metab*. 1996;81(11):3909-3913.
547 **36.** Légrádi G, Emerson CH, Ahima RS, Flier JS, Lechan RM. Leptin prevents fasting-
548 induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid
549 in neurons of the hypothalamic paraventricular nucleus. *Endocrinology*.
550 1997;138(6):2569-2576.
551 **37.** Nillni EA, Vaslet C, Harris M, Hollenberg A, Bjørbak C, Flier JS. Leptin regulates
552 prothyrotropin-releasing hormone biosynthesis. Evidence for direct and indirect

553 pathways. *J Biol Chem*. 2000;275(46):36124-36133.

554 **38.** Harris M, Aschkenasi C, Elias CF, Chandrankunnel A, Nillni EA, Bjøorbaek C,
555 Elmquist JK, Flier JS, Hollenberg AN. Transcriptional regulation of the thyrotropin-
556 releasing hormone gene by leptin and melanocortin signaling. *J Clin Invest*.
557 2001;107(1):111-120.

558 **39.** Berghout A, Wiersinga WM, Smits NJ, Touber JL. Determinants of thyroid volume as
559 measured by ultrasonography in healthy adults in a non-iodine deficient area. *Clin*
560 *Endocrinol (Oxf)*. 1987;26(3):273-280.

561 **40.** Barrère X, Valeix P, Preziosi P, Bensimon M, Pelletier B, Galan P, Hercberg S.
562 Determinants of thyroid volume in healthy French adults participating in the
563 SU.VI.MAX cohort. *Clin Endocrinol (Oxf)*. 2000;52(3):273-278.

564 **41.** Gómez JM, Maravall FJ, Gómez N, Gumà A, Casamitjana R, Soler J. Pituitary-
565 thyroid axis, thyroid volume and leptin in healthy adults. *Horm Metab Res*.
566 2002;34(2):67-71.

567 **42.** Guo W, Tan L, Dong S, Jin Y, Zhu M, Wei H, Chen Y, Fan L, Du C, Zhang W. New
568 Reference Values for Thyroid Volume and a Comprehensive Assessment for
569 Influencing Factors in Chinese Adults with Iodine Sufficiency. *Eur Thyroid J*.
570 2021;10(6):447-454.

571 **43.** Srivastava S, Dighe M, Möller K, Chammas MC, Dong Y, Cui XC, Dietrich CF.
572 Ultrasound measurements and normal findings in the thyroid gland. *Med Ultrason*.
573 2024; doi: 10.11152/mu-4451.

574 **44.** Fuse Y, Ito Y, Shishiba Y, Irie M. Current Iodine Status in Japan: A Cross-sectional
575 Nationwide Survey of Schoolchildren, 2014-2019. *J Clin Endocrinol Metab*.
576 2022;107(5):e2065-e2079.

577 **Figure Legends**

578 **Figure 1. Flowchart illustrating the establishment of cohorts in this prospective study.** n,
579 number of subjects; TPOAb, anti-thyroperoxidase antibody; SITSH, syndrome of
580 inappropriate secretion of TSH; FDG: ^{18}F-fluorodeoxyglucose.

581 **Figure 2. Prevalence of abnormal findings on thyroid examinations in the Original**
582 **cohort.** The actual number of subjects is shown in panels A, C, D, and E. The percentage of
583 subjects with abnormal findings is shown in panels B and F. Thyroid nodules were classified
584 by maximum diameter.

585 **Figure 3. Associations between characteristics and thyroid function in the Original**
586 **cohort.** (A) Scatter plot of serum TSH and free T4 (fT4) levels. (B) Illustration of the
587 exclusion criteria for the analyses presented in Figures 3 and 4, overlaid on a scatter plot. (C–
588 E) Trends in thyroid function according to age (see Supplemental Table 2 for the actual
589 values). (F–H) Trends in thyroid function according to body mass index (BMI) (see
590 Supplemental Table 5 for actual values). Gray violin plots show the distribution of the data,
591 and black circles with connecting lines represent mean ± SD. Log-transformed TSH values
592 were used for statistical analyses because of their log-normal distribution. Trend analyses
593 were conducted by assigning the median value of each category and modeling it as a
594 continuous variable in regression analyses.

595 **Figure 4. Associations between thyroid examination results and thyroid function in the**
596 **Original cohort.** (A–C) Differences in thyroid function according to the presence of
597 increased blood flow on thyroid ultrasonography (see Supplemental Table 6 for actual
598 values). (D–F) Differences in thyroid function according to the presence of diffuse FDG
599 uptake (see Supplemental Table 6 for actual values). (G–I) Trends in thyroid function
600 according to thyroid nodule size, classified by maximum diameter (see Supplemental Table 7
601 for the actual values). (J–L) Trends in thyroid function according to thyroid volume (see
602 Supplemental Table 8 for actual values). Data from 183 subjects were excluded because of

technical issues in volume measurement using ultrasonography. Gray violin plots show the distribution of the data, and black circles with connecting lines represent mean ± SD. Student's *t* test was used for panels A–F. Trend analyses were performed for panels G–L.

Figure 5. Associations between TPOAb titers and thyroid examination results in the TPOAb cohort. (A) Number of TPOAb-positive subjects. (B–E) Prevalence of abnormal findings in TPOAb-positive subjects; any thyroid dysfunction (B), increased blood flow (C), diffuse FDG uptake (D), and any thyroid nodules (E). (F) Exclusion criteria for analyses in panels G–I overlaid on the scatter plot. (G–I) Differences in thyroid function according to TPOAb positivity (see Supplemental Table 11 for the actual values). Gray violin plots show the distribution of the data, and black circles with connecting lines represent mean ± SD. Student's *t* test was used.

Figure 6. Associations between characteristics and thyroid size in the Thyroid-healthy cohort. (A–D) Trends in thyroid size according to age (see Supplemental Table 12 for the actual values). (E–H) Trends in thyroid size according to height (see Supplemental Table 13 for the actual values). (I–L) Trends in thyroid size according to body weight (see Supplemental Table 14 for actual values). Two male subjects weighing < 50.0 kg were excluded because of the small sample size. Gray violin plots show the distribution of the data, and black circles with connecting lines represent mean ± SD.

Table 1. Characteristics and prevalence of abnormal findings in the Original cohort

	All (n = 4407)	Male (n = 2643)	Female (n = 1764)	*p*
Age (year)	52.9 (11.3)	53.2 (11.0)	52.3 (11.9)	0.0114
Height (cm)	166.2 (8.7)	171.5 (6.1)	158.3 (5.5)	< 0.0001
Body weight (kg)	66.0 (14.1)	73.5 (11.5)	54.7 (9.3)	< 0.0001
BMI (kg/m^2)	23.7 (3.8)	25.0 (3.5)	21.8 (3.6)	< 0.0001
Thyroid function				
TSH (μIU/mL)	1.952 (2.245)	1.859 (1.972)	2.091 (2.596)	0.0001
fT4 (ng/dL)	1.288 (0.200)	1.313 (0.180)	1.250 (0.221)	< 0.0001
fT3 (pg/mL)	3.08 (0.58)	3.19 (0.39)	2.93 (0.76)	< 0.0001
Thyroid dysfunction				
No n (%)	4151 (94.19%)	2505 (94.78%)	1646 (93.31%)	0.0485
Yes n (%)	256 (5.81%)	138 (5.22%)	118 (6.69%)	
Overt thyrotoxicosis	27 (0.61%)	15 (0.57%)	12 (0.68%)	
Subclinical thyrotoxicosis	104 (2.36%)	69 (2.61%)	35 (1.98%)	
Subclinical hypothyroidism	118 (2.68%)	52 (1.97%)	66 (3.74%)	
Overt hypothyroidism	7 (0.16%)	2 (0.08%)	5 (0.28%)	
Increased blood flow				
No n (%)	4299 (97.55%)	2608 (98.68%)	1691 (95.86%)	< 0.0001
Yes n (%)	108 (2.45%)	35 (1.32%)	73 (4.14%)	
Diffuse FDG uptake				
No n (%)	4256 (96.57%)	2604 (98.52%)	1652 (93.65%)	< 0.0001
Yes n (%)	151 (3.43%)	39 (1.48%)	112 (6.35%)	
Thyroid nodule				
No n (%)	2657 (60.29%)	1763 (66.71%)	894 (50.68%)	< 0.0001
Yes n (%)	1750 (39.71%)	880 (33.29%)	870 (49.32%)	
< 5.0 mm	667 (15.14%)	393 (14.87%)	274 (15.53%)	
5.0–9.9 mm	705 (16.00%)	329 (12.45%)	376 (21.32%)	
10.0–19.9 mm	315 (7.15%)	133 (5.03%)	182 (10.32%)	
≥ 20.0 mm	63 (1.43%)	25 (0.95%)	38 (2.15%)	

BMI, body mass index; fT4, free T4; fT3, free T3; FDG, ^{18}F-fluorodeoxyglucose. Continuous variables are expressed as mean (SD). Comparisons between males and females were performed using the Student's *t*-test or Fisher's exact test, as appropriate. TSH values were log-transformed for statistical analyses due to their log-normal distribution.

Table 2. Characteristics and prevalence of abnormal findings in the Original cohort, classified by thyroid dysfunction

	Euthyroid (n = 4151)	Overt thyrotoxicosis (n = 27)	Subclinical thyrotoxicosis (n = 104)	Subclinical hypothyroidism (n = 118)	Overt hypothyroidism (n = 7)
Thyroid function					
TSH (μIU/mL)	1.805 (0.932)	0.185 (0.195)****	0.382 (0.116)****	7.041 (4.487)****	33.436 (31.148)****
fT4 (ng/dL)	1.285 (0.166)	2.295 (0.970)****	1.333 (0.137)**	1.161 (0.142)****	0.677 (0.194)****
fT3 (pg/mL)	3.07 (0.39)	6.06 (4.79)****	3.18 (0.48)**	2.89 (0.33)****	2.68 (0.47)**
Age	52.8 (11.3)	47.0 (8.2)**	51.7 (10.3)	58.1 (13.3)****	60.0 (11.5)
Sex					
Male n (%)	2505 (60.35%)	15 (55.56%)	69 (66.35%)	52 (44.07%)***	2 (28.57%)
Female n (%)	1646 (39.65%)	12 (44.44%)	35 (33.65%)	66 (55.93%)	5 (71.43%)
Increased blood flow					
No n (%)	4071 (98.07%)	19 (70.37%)****	101 (97.12%)	106 (89.83%)****	2 (28.57%)****
Yes n (%)	80 (1.93%)	8 (29.63%)	3 (2.88%)	12 (10.17%)	5 (71.43%)
Diffuse FDG uptake					
No n (%)	4026 (96.99%)	23 (85.19%)**	100 (96.15%)	106 (89.83%)***	1 (14.29%)****
Yes n (%)	125 (3.01%)	4 (14.81%)	4 (3.85%)	12 (10.17%)	6 (85.71%)
Thyroid nodule					
No n (%)	2527 (60.88%)	18 (66.67%)	45 (43.27%)***	64 (54.24%)	3 (42.86%)
Yes n (%)	1624 (39.12%)	9 (33.33%)	59 (56.73%)	54 (45.76%)	4 (57.14%)

Continuous values are expressed as mean (SD). Statistical analyses were performed for each group in comparison with the euthyroid group. Thyroid function and age were analyzed using the Student's *t*-test. TSH values were log-transformed for statistical analyses due to their log-normal distribution. Sex, FDG uptake, increased blood flow, and thyroid nodules were analyzed using Fisher's exact test. $^{**}p < 0.01$, $^{***}p < 0.001$, and $^{****}p < 0.0001$.

Table 3. Characteristics and prevalence of abnormal findings in the TPOAb cohort, classified by TPOAb titers

	< 16.0 IU/mL (n = 2246)	16.0–31.9 IU/mL (n = 63)	32.0–127.9 IU/mL (n = 41)	≥ 128.0 IU/mL (n = 70)
Thyroid dysfunction				
No	2135 (95.06%)	59 (93.65%)	39 (95.12%)	53 (75.71%)****
Yes	111 (4.94%)	4 (6.35%)	2 (4.88%)	17 (24.29%)
Overt thyrotoxicosis	13 (0.58%)	0 (0.00%)	1 (2.44%)	3 (4.29%)
Subclinical thyrotoxicosis	46 (2.05%)	1 (1.59%)	1 (2.44%)	1 (1.43%)
Subclinical hypothyroidism	51 (2.27%)	3 (4.76%)	0 (0.00%)	10 (14.29%)
Overt hypothyroidism	1 (0.04%)	0 (0.00%)	0 (0.00%)	3 (4.29%)
Age	52.2 (11.2)	50.5 (12.2)	51.3 (10.9)	54.4 (10.7)
Sex				
Male n (%)	1404 (62.51%)	32 (50.79%)*	17 (41.46%)**	29 (41.43%)***
Female n (%)	842 (37.49%)	31 (49.21%)	24 (58.54%)	41 (58.57%)
Increased blood flow				
No n (%)	2221 (98.89%)	57 (90.48%)***	33 (80.49%)****	35 (50.00%)****
Yes n (%)	25 (1.11%)	6 (9.52%)	8 (19.51%)	35 (50.00%)
Diffuse FDG uptake				
No n (%)	2218 (98.75%)	57 (90.48%)***	32 (78.05%)****	35 (50.00%)****
Yes n (%)	28 (1.25%)	6 (9.52%)	9 (21.95%)	35 (50.00%)
Thyroid nodule				
No n (%)	1360 (60.55%)	36 (57.14%)	28 (68.29%)	39 (55.71%)
Yes n (%)	886 (39.45%)	27 (42.86%)	13 (31.71%)	31 (44.29%)

TPOAb, anti-thyroperoxidase antibody. Continuous values are expressed as mean (SD). Statistical analyses were performed for each group in comparison with the < 16.0 IU/mL group. Age was analyzed using Student's *t*-test, and all other variables were analyzed using Fisher's exact test. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, and ****$p < 0.0001$.

Table 4. Multivariate regression analysis for determinants of thyroid function

	Model 1			Model 2		
	logTSH	fT4	fT3	logTSH	fT4	fT3
R^2	0.039	0.062	0.209	0.096	0.107	0.212
Intercept	−0.023	1.362	3.036	0.199	1.257	3.016
Age (year)	0.004****	−0.002****	−0.007****	0.004****	−0.002****	−0.007****
Sex (male to female)	−0.023***	0.034****	0.128****	0.002	0.020****	0.122****
BMI (kg/m^2)	0.001	0.001	0.017****	0.005**	−0.001	0.016****
Increased blood flow				0.063**	−0.037**	−0.018
Diffuse FDG uptake				0.026	−0.031*	0.007
Thyroid volume (g)				−0.014****	0.009****	0.005*
TPOAb ≥ 128.0 IU/mL				0.062***	0.009	0.019

R^2: coefficient of determination. Results are represented as estimates. "log" denotes the base-10 logarithm.

*$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, and ****$p < 0.0001$.

Table 5. Characteristics and thyroid size on ultrasonography in the Thyroid-healthy cohort

	All (n = 1840)	Male (n = 1187)	Female (n = 653)	*p*
Age	51.7 (10.9)	52.1 (10.6)	51.1 (11.5)	0.0780
Height (cm)	167.1 (8.5)	171.8 (5.8)	158.4 (5.5)	< 0.0001
Weight (kg)	67.3 (14.1)	74.0 (11.6)	55.0 (9.3)	< 0.0001
BMI (kg/m^2)	23.9 (3.9)	25.1 (3.5)	21.9 (3.6)	< 0.0001
Thyroid function				
TSH (μIU/mL)	1.782 (0.924)	1.727 (0.896)	1.881 (0.967)	0.0007
fT4 (ng/dL)	1.291 (0.161)	1.314 (0.164)	1.248 (0.147)	< 0.0001
fT3 (pg/mL)	3.11 (0.38)	3.22 (0.35)	2.91 (0.36)	< 0.0001
Thyroid nodule				
No n (%)	1226 (66.63%)	844 (71.10%)	382 (58.50%)	< 0.0001
Yes n (%)	614 (33.37%)	343 (28.90%)	271 (41.50%)	
< 5.0 mm	318 (17.28%)	197 (16.60%)	121 (18.53%)	
5.0–9.9 mm	296 (16.09%)	146 (12.30%)	150 (22.97%)	
Isthmus (mm)				
Thickness	2.3 (0.8)	2.5 (0.8)	1.9 (0.7)	< 0.0001
Right lobe (mm)				
Transverse diameter	15.9 (2.9)	16.7 (2.8)	14.4 (2.5)	< 0.0001
Anteroposterior diameter	13.9 (2.7)	14.8 (2.5)	12.2 (2.1)	< 0.0001
Longitudinal diameter	49.7 (5.5)	50.2 (5.3)	48.6 (5.7)	< 0.0001
Left lobe (mm)				
Transverse diameter	15.5 (2.8)	16.0 (2.8)	14.5 (2.3)	< 0.0001
Anteroposterior diameter	12.1 (2.8)	13.0 (2.6)	10.5 (2.4)	< 0.0001
Longitudinal diameter	47.2 (6.0)	47.9 (5.7)	46.0 (6.3)	< 0.0001
Thyroid volume (g)	10.6 (3.9)	11.9 (3.8)	8.3 (2.8)	< 0.0001

Continuous variables are expressed as mean (SD). Comparisons between male and female groups were performed using the Student's *t*-test or Fisher's exact test, as appropriate. TSH values were log-transformed for statistical analyses due to their log-normal distribution.

Table 6. Reference ranges for individual thyroid dimensions measured by ultrasonography

	Male	Female
Isthmus (mm)		
Thickness	1.1–4.4	0.9–3.8
Right lobe (mm)		
Transverse diameter	11.8–22.8	9.7–18.7
Anteroposterior diameter	10.0–20.5	8.1–16.4
Longitudinal diameter	38.8–59.1	37.0–58.1
Left lobe (mm)		
Transverse diameter	10.9–21.7	10.3–18.9
Anteroposterior diameter	7.8–18.2	6.0–15.5
Longitudinal diameter	36.1–58.1	33.0–57.5
Thyroid volume (g)	6.0–20.8	4.1–13.7

The 2.5th–97.5th percentile was calculated in the Thyroid-healthy cohort, excluding subjects with nodules 5.0–9.9 mm.

Figure 1


Initial checkup data of all subjects between 2016 and 2021
n = 4651
No blood test n = 5
No informed consent n = 111
Medical history of thyroid disease n = 128
Graves' disease n = 37
Levothyroxine replacement n = 37
Thyroid cancer n = 36
Surgery for thyroid nodules n = 13
Subacute thyroiditis n = 5
Original cohort n = 4407
No TPOAb test n = 1987
TPOAb cohort n = 2420
No available data on thyroid volume n = 130
TSH outside the reference range n = 116
SITSH n = 1
Thyroid nodules ≥ 10 mm n = 175
TPOAb positive n = 130
Increased blood flow n = 14
Diffuse FDG uptake n = 14
Thyroid-healthy cohort n = 1840

Figure 2


A
Thyroid dysfunction
All
256
4151
Male
84
2505
Female
118
1646
Yes
No
0
1000
2000
3000
4000
5000
Subjects (n)
B
Classification of thyroid dysfunction
All
27
104
118
7
Male
15
69
52
2
Female
12
35
66
5
Overt thyrotoxicosis
Subclinical thyrotoxicosis
Subclinical hypothyroidism
Overt hypothyroidism
0%
20%
40%
60%
80%
100%
Percentage in subjects with thyroid dysfunction
C
Increased blood flow
All
108
4299
Male
35
2608
Female
73
1691
Yes
No
0
1000
2000
3000
4000
5000
Subjects (n)
D
Diffuse FDG uptake
All
151
4256
Male
39
2604
Female
112
1652
Yes
No
0
1000
2000
3000
4000
5000
Subjects (n)
E
Thyroid nodule
All
1750
2657
Male
880
1763
Female
870
894
Yes
No
0
1000
2000
3000
4000
5000
Subjects (n)
F
Classification of thyroid nodule
All
667
705
315
63
Male
393
329
133
25
Female
274
376
182
38
< 5.0 mm
5.0–9.9 mm
10.0–19.9 mm
>= 20.0 mm
0%
20%
40%
60%
80%
100%
Percentage in subjects with thyroid nodule

Figure 3


A
Serum fT4 (ng/dL)
Serum TSH (μIU/mL)
B
Excluded
Subnormal range
Excluded
Reference range
SITSH (Excluded)
Serum fT4 (ng/dL)
Serum TSH (μIU/mL)
C
Male
Female
p < 0.0001
p < 0.0001
Serum TSH (μIU/mL)
Age (year)
D
Male
Female
p < 0.0001
p = 0.5625
Serum fT4 (ng/dL)
Age (year)
E
Male
Female
p < 0.0001
p = 0.0229
Serum fT3 (pg/mL)
Age (year)
F
Male
Female
p = 0.2328
p = 0.0024
Serum TSH (μIU/mL)
BMI (kg/m²)
G
Male
Female
p = 0.0523
p = 0.4194
Serum fT4 (ng/dL)
BMI (kg/m²)
H
Male
Female
p < 0.0001
p < 0.0001
Serum fT3 (pg/mL)
BMI (kg/m²)

Figure 4


A
Male
Female
p < 0.0001
p < 0.0001
Serum TSH (µIU/mL)
100
10
1
0.1
0.01
No
Yes
No
Yes
Increased blood flow
B
Male
Female
p = 0.0084
p = 0.0115
Serum fT4 (ng/dL)
2.5
2.0
1.5
1.0
0.5
No
Yes
No
Yes
Increased blood flow
C
Male
Female
p = 0.8405
p = 0.7826
Serum fT3 (pg/mL)
5
4
3
2
1
No
Yes
No
Yes
Increased blood flow
D
Male
Female
p = 0.0008
p < 0.0001
Serum TSH (µIU/mL)
100
10
1
0.1
0.01
No
Yes
No
Yes
Diffuse FDG uptake
E
Male
Female
p = 0.0138
p = 0.0495
Serum fT4 (ng/dL)
2.5
2.0
1.5
1.0
0.5
No
Yes
No
Yes
Diffuse FDG uptake
F
Male
Female
p = 0.7677
p = 0.4111
Serum fT3 (pg/mL)
5
4
3
2
1
No
Yes
No
Yes
Diffuse FDG uptake
G
Male
Female
p = 0.1485
p = 0.0020
Serum TSH (µIU/mL)
100
10
1
0.1
0.01
No
< 5.0
5.0–9.9
10.0–19.9
>= 20.0
No
< 5.0
5.0–9.9
10.0–19.9
>= 20.0
Thyroid nodule (mm)
H
Male
Female
p = 0.5826
p = 0.0028
Serum fT4 (ng/dL)
2.5
2.0
1.5
1.0
0.5
No
< 5.0
5.0–9.9
10.0–19.9
>= 20.0
No
< 5.0
5.0–9.9
10.0–19.9
>= 20.0
Thyroid nodule (mm)
I
Male
Female
p = 0.0181
p = 0.0844
Serum fT3 (pg/mL)
5
4
3
2
1
No
< 5.0
5.0–9.9
10.0–19.9
>= 20.0
No
< 5.0
5.0–9.9
10.0–19.9
>= 20.0
Thyroid nodule (mm)
J
Male
Female
p < 0.0001
p < 0.0001
Serum TSH (µIU/mL)
100
10
1
0.1
0.01
< 5.0
5.0–9.9
10.0–14.9
15.0–19.9
>= 20.0
< 5.0
5.0–9.9
10.0–14.9
15.0–19.9
>= 20.0
Thyroid volume (g)
K
Male
Female
p < 0.0001
p < 0.0001
Serum fT4 (ng/dL)
2.5
2.0
1.5
1.0
0.5
< 5.0
5.0–9.9
10.0–14.9
15.0–19.9
>= 20.0
< 5.0
5.0–9.9
10.0–14.9
15.0–19.9
>= 20.0
Thyroid volume (g)
L
Male
Female
p < 0.0001
p < 0.0001
Serum fT3 (pg/mL)
5
4
3
2
1
< 5.0
5.0–9.9
10.0–14.9
15.0–19.9
>= 20.0
< 5.0
5.0–9.9
10.0–14.9
15.0–19.9
>= 20.0
Thyroid volume (g)

Figure 5


A
TPOAb positivity
174
2246
All
78
1404
Male
96
842
Female
Yes
No
0
500
1000
1500
2000
2500
3000
Subjects (n)
B
Thyroid dysfunction
111
2135
TPOAb negative
23
151
TPOAb positive
Yes
No
0%
50%
100%
Percentage in each group
C
Increased blood flow
25
2221
TPOAb negative
49
125
TPOAb positive
Yes
No
0%
50%
100%
Percentage in each group
D
Diffuse FDG uptake
28
2218
TPOAb negative
50
124
TPOAb positive
Yes
No
0%
50%
100%
Percentage in each group
E
Thyroid nodule
886
1360
TPOAb negative
71
103
TPOAb positive
Yes
No
0%
50%
100%
Percentage in each group
F
Excluded
Subnormal range
Excluded
Reference range
SITSH (Excluded)
Serum fT4 (ng/dL)
Serum TSH (µIU/mL)
G
Male
Female
p = 0.0103
p = 0.0002
Serum TSH (µIU/mL)
TPOAb positivity
H
Male
Female
p = 0.1313
p = 0.0904
Serum fT4 (ng/dL)
TPOAb positivity
I
Male
Female
p = 0.8263
p = 0.7054
Serum fT3 (pg/mL)
TPOAb positivity

Figure 6


A
Male
Female
p = 0.6311
p = 0.1106
Isthmus thickness (mm)
Age (year)
B
Male
Female
p = 0.9177
p = 0.1648
Transverse diameter (mm)
Age (year)
C
Male
Female
p = 0.1052
p = 0.1524
anteroposterior diameter (mm)
Age (year)
D
Male
Female
p < 0.0001
p < 0.0001
Longitudinal diameter (mm)
Age (year)
E
Male
Female
p = 0.7027
p = 0.5316
Isthmus thickness (mm)
Height (cm)
F
Male
Female
p = 0.0047
p = 0.3349
Transverse diameter (mm)
Height (cm)
G
Male
Female
p = 0.0578
p = 0.8986
anteroposterior diameter (mm)
Height (cm)
H
Male
Female
p < 0.0001
p < 0.0001
Longitudinal diameter (mm)
Height (cm)
I
Male
Female
p < 0.0001
p < 0.0001
Isthmus thickness (mm)
Body weight (g)
J
Male
Female
p < 0.0001
p < 0.0001
Transverse diameter (mm)
Body weight (g)
K
Male
Female
p < 0.0001
p = 0.0001
anteroposterior diameter (mm)
Body weight (g)
L
Male
Female
p = 0.0450
p = 0.6798
Longitudinal diameter (mm)
Body weight (g)